HQL Insider Trading
Insider Ownership Percentage: 10.06%
Insider Buying (Last 12 Months): $970,526.20
Insider Selling (Last 12 Months): $4,076,654.28
Abrdn Life Sciences Investors Insider Trading History Chart
This chart shows the insider buying and selling history at Abrdn Life Sciences Investors by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Abrdn Life Sciences Investors Share Price & Price History
Current Price: $12.27
Price Change: ▼ Price Decrease of -0.21 (-1.68%)
As of 05/30/2025 04:59 PM ET
Abrdn Life Sciences Investors Insider Trading History
SEC Filings (Institutional Ownership Changes) for Abrdn Life Sciences Investors (NYSE:HQL)
32.21% of Abrdn Life Sciences Investors stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at HQL by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
Abrdn Life Sciences Investors Institutional Trading History
Data available starting January 2016
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Read More on Abrdn Life Sciences Investors
Today's Range
Now: $12.27
52 Week Range
Now: $12.27
Volume
143,945 shs
Average Volume
105,436 shs
Market Capitalization
$354.26 million
P/E Ratio
N/A
Dividend Yield
15.30%
Beta
0.76
Who are the company insiders with the largest holdings of Abrdn Life Sciences Investors?
Who are the major institutional investors of Abrdn Life Sciences Investors?
Which institutional investors are selling Abrdn Life Sciences Investors stock?
During the last quarter, HQL stock was sold by these institutional investors:
- Absolute Investment Advisers LLC
- AQR Arbitrage LLC
- Penserra Capital Management LLC
- Quarry LP
- 1607 Capital Partners LLC
- Readystate Asset Management LP
- Invesco Ltd.
- Atlantic Union Bankshares Corp
Which institutional investors are buying Abrdn Life Sciences Investors stock?
Within the previous quarter, HQL stock was bought by institutional investors including:
- Flagship Harbor Advisors LLC
- Raymond James Financial Inc.
- Formidable Asset Management LLC
- LPL Financial LLC
- Allspring Global Investments Holdings LLC
- Needham Investment Management LLC
- Royal Bank of Canada
- Shaker Financial Services LLC
Within the previous year, these company insiders have bought Abrdn Life Sciences Investors stock:
- Saba Capital Management, LP (Major Shareholder)
- Daniel R Omstead (President)
- Bill Maher (Director)
- Kathleen Goetz (Director)
- Rose Dimartino (Director)
- Todd Reit (Director)
Learn More investors buying Abrdn Life Sciences Investors stock.